What is the address of MavSAN Med?

The registered office of MavSAN Med is located at Jozef De Blockstraat 12, 2830 Willebroek.

Is MavSAN Med still active?

Yes. According to the CBE (2 November 2026) MavSAN Med is active, legal situation “Normale toestand”, started on 13 January 2023.

Is MavSAN Med registered on Peppol?

Yes, MavSAN Med is registered on the Peppol network with ID 0208:0797148671.

What is the enterprise number of MavSAN Med?

The enterprise number of MavSAN Med is BE0797148671.

When was MavSAN Med founded?

MavSAN Med was founded on 13 January 2023.

Who are the directors of MavSAN Med?

According to the 2025 annual accounts, the directors of MavSAN Med are: Raïssa Ineza Ngabe, Santos Mavutukidi .

Is MavSAN Med a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 January 2023; 3 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 1 events from the Belgian Official Gazette processed.

How much profit did MavSAN Med make in 2025?

MavSAN Med posted a profit after taxes of € 20,533 in financial year 2025.

What is the revenue of MavSAN Med?

As a small company, MavSAN Med is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 39,485.

MavSAN Med (Private Limited) - Willebroek - BE0797148671

Dossier MavSAN Med, printed on 2 November 2026 from databakkes.be/en/0797148671/mavsan-med. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MavSAN Med from Willebroek, company number BE0797148671, closed financial year 2025 with a result of € 20,533 after tax. For that financial year MavSAN Med recorded a gross margin of € 39,485 and equity of € 32,157. Compared with financial year 2024, the result moved from € 25,731 to € 20,533. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Growing

€ 32,157

▲ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 20,533

▼ 20% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 26,039

▼ 31% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 20,000 paid out

97 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 8,973

▼ 45% vs 2024

Of which on lease € 2,772.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 8,933

▼ 32% vs 2024

€ 4,353 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 1,602

▲ 11% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 23,204

▲ 15% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 46,127 Gross margin 2023: € 46,127 First fiscal year in the series	€ 45,858 Gross margin 2024: € 45,858 ▼ 1% vs 2023 (€ 46,127) Unfavourable step	€ 39,485 Gross margin 2025: € 39,485 ▼ 14% vs 2024 (€ 45,858) Unfavourable step	▼ 14%
Profit after taxes	€ 33,393 Profit after taxes 2023: € 33,393 First fiscal year in the series	€ 25,731 Profit after taxes 2024: € 25,731 ▼ 23% vs 2023 (€ 33,393) Unfavourable step	€ 20,533 Profit after taxes 2025: € 20,533 ▼ 20% vs 2024 (€ 25,731) Unfavourable step	▼ 20%
Equity	€ 20,893 Equity 2023: € 20,893 First fiscal year in the series	€ 31,624 Equity 2024: € 31,624 ▲ 51% vs 2023 (€ 20,893) Favourable step	€ 32,157 Equity 2025: € 32,157 ▲ 2% vs 2024 (€ 31,624) Favourable step	▲ 2%
Total debts	€ 44,177 Total debts 2023: € 44,177 First fiscal year in the series	€ 49,689 Total debts 2024: € 49,689 ▲ 12% vs 2023 (€ 44,177) Unfavourable step	€ 53,738 Total debts 2025: € 53,738 ▲ 8% vs 2024 (€ 49,689) Unfavourable step	▲ 8%
Cash	€ 46,119 Cash 2023: € 46,119 First fiscal year in the series	€ 37,855 Cash 2024: € 37,855 ▼ 18% vs 2023 (€ 46,119) Unfavourable step	€ 26,039 Cash 2025: € 26,039 ▼ 31% vs 2024 (€ 37,855) Unfavourable step	▼ 31%
Retained profit	€ 18,393 Retained profit 2023: € 18,393 First fiscal year in the series	€ 29,124 Retained profit 2024: € 29,124 ▲ 58% vs 2023 (€ 18,393) Favourable step	€ 29,657 Retained profit 2025: € 29,657 ▲ 2% vs 2024 (€ 29,124) Favourable step	▲ 2%
Dividend	€ 15,000 Dividend 2023: € 15,000 First fiscal year in the series	€ 15,000 Dividend 2024: € 15,000 Unchanged (€ 15,000) Unchanged	€ 20,000 Dividend 2025: € 20,000 ▲ 33% vs 2024 (€ 15,000) Unchanged	▲ 33%
Bank debt	€ 17,000 Bank debt 2023: € 17,000 First fiscal year in the series	€ 13,069 Bank debt 2024: € 13,069 ▼ 23% vs 2023 (€ 17,000) Favourable step	€ 8,933 Bank debt 2025: € 8,933 ▼ 32% vs 2024 (€ 13,069) Favourable step	▼ 32%
Balance sheet total	€ 65,070 Balance sheet total 2023: € 65,070 First fiscal year in the series	€ 81,313 Balance sheet total 2024: € 81,313 ▲ 25% vs 2023 (€ 65,070) Unchanged	€ 85,895 Balance sheet total 2025: € 85,895 ▲ 6% vs 2024 (€ 81,313) Unchanged	▲ 6%

Key figures of MavSAN Med, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MavSAN Med?

What happened at MavSAN Med in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: profit of € 20,533 (▼ 20% vs 2024). filed late Source: NBB ↗
2024 Raïssa Ineza Ngabe became a director. NBB
Jan 17, 2023 Incorporation, published in the Gazette. Source: Staatsblad ↗
Jan 13, 2023 New establishment in Willebroek. KBO
2023 Santos Mavutukidi became a director. NBB

In short

From € 33,393 profit in 2023 to € 20,533 profit in 2025.

Paid € 29,504 in corporate taxes since 2023.

Best year ever: 2023, with € 33,393 profit.

Paid out € 50,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Raïssa Ineza Ngabe Santos Mavutukidi

MavSAN Med

Behind MavSAN Med are Raïssa Ineza Ngabe and Santos Mavutukidi .

Directors

According to the 2025 annual accounts

Raïssa Ineza Ngabe

Director

since 2024

Santos Mavutukidi

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Jozef De Blockstraat 12

2830 Willebroek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

17 January 2023 Source: Deed ↗

Mavutukidi Santos(oprichter) 100%

Details

Company number: 0797.148.671
VAT number: BE 0797.148.671
Registered office: Jozef De Blockstraat 12, 2830 Willebroek
Names & denominations: MavSAN Med
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 13 January 2023
Peppol: Active · Active since 4 Sept 2025

View on CBE Public ↗ Annual accounts (NBB) ↗